RFA-TR-21-008: Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on April 19, 2021.
From the official notice on Grants.gov, last changed January 15, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsOptional
- Funded byNCATS
- Median yearly award$410,382
- Typical project length3 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-TR-21-008 were run by National Center for Advancing Translational Sciences (NCATS, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-TR-21-008 in the NIH Guide.
Key dates
| Posted | January 15, 2021 |
|---|---|
| Deadline | April 19, 2021 |
| Archived by Grants.gov | May 25, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (82% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for multi-disciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow.
Funded under RFA-TR-21-008 so far
NIH funded 5 projects under RFA-TR-21-008 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $410,382.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Using electronic medical record data to shorten diagnostic odysseys for rare genetic disorders in children and adults in two New York City health care settings | Icahn School of Medicine at Mount Sinai | 2026 | $473,116 |
| Expanding Access to Genetic Evaluation Through Virtual Platforms | Baylor College of Medicine | 2026 | $465,000 |
| Virtual Platforms for Genetics Evaluation in the Medically Underserved | Baylor College of Medicine | 2023 | $302,000 |
| Using electronic medical record data to shorten diagnostic odysseys for rare genetic disorders in children and adults in two New York City health care settings | Icahn School of Medicine at Mount Sinai | 2023 | $338,000 |
| Machine-Assisted Interdisciplinary Approach For Early Clinical Evaluation of Neurodevelopmental Disorders | Children's Research Institute | 2023 | $350,274 |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-TR-21-008 still open?
No. It closed on April 19, 2021.
Who can apply for Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)?
Closed April 19, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-TR-21-008?
NIH RePORTER lists 5 projects funded under RFA-TR-21-008 in fiscal 2022 to 2026, at 3 institutions. The most were at Icahn School of Medicine at Mount Sinai, Baylor College of Medicine, Children's Research Institute.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)